Advertisement
U.S. markets close in 5 hours 29 minutes

Century Therapeutics, Inc. (IPSC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.1700-0.1000 (-2.34%)
As of 10:15AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close4.2700
Open4.2300
Bid4.0100 x 100
Ask4.3000 x 100
Day's Range4.0500 - 4.2500
52 Week Range1.2800 - 5.5100
Volume13,771
Avg. Volume222,567
Market Cap270.291M
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-2.3000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IPSC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Century Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/24/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • GlobeNewswire

    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

    SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. “We are fortunate to have Tim and Paul join us at this key st

  • Zacks

    Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?

    Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • GlobeNewswire

    Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

    PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET. A replay of the event will be available on the “Eve